Beta-blocking agents in patients with insulin resistance: Effects of vasodilating beta-blockers

Blood Pressure

Volumn 8, Issue 5-6, 1999, Pages 261-268

  Jacob, Stephan ^a   Balletshofer, Bernd ^a   Henriksen, Erik J ^b   Volk, Annette ^a   Mehnert, Birgit ^a   Löblein, Klaus ^a   Häring, Hans Ulrich ^a   Rett, Kristian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antihypertensive treatment; Atherogenic risk factors; Betablocking agents; Insulin sensitivity; Vasodilating beta blocker

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CELIPROLOL; DILEVALOL; DIURETIC AGENT; METOPROLOL; PINDOLOL; PROPRANOLOL;

ANTIHYPERTENSIVE THERAPY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; ESSENTIAL HYPERTENSION; HUMAN; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; OXIDATIVE STRESS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0033501503     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599439463     Document Type: Review

References (71)

1. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985; 75: 809-17.
2. DeFronzo RA, Ferrannini E. Insulin resistance. A multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
3. Dieterle P, Fehm H, Stroder W, Henner J, Bottermann P, Schwarz K. [Asymptomatic diabetes mellitus in normal weight subjects with hypertension. Studies on glucose tolerance, serum insulin and nonesterified fatty acids in essential hypertension], Dtsch Med Wochenschr 1967; 92: 2376-81.
4. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-74.
5. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.
6. Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419-23.
7. Allemann Y, Horber FF, Colombo M, et al. Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet 1993; 341: 327-31.
8. Ferrari P, Weidmann P, Shaw S, et al. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589-96.
9. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-31.
10. Baron AD. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996; 45 Suppl 1: S105-9.
11. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
12. Lind L, Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 1993; 125: 1494-7.
13. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187-202.
14. Baron AD, Brechtel Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993; 21: 129-35.
15. Lind L, Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 1993; 125: 1494-7.
16. Balletshofer B, Rittig K, Enderle M, et al. Disturbed flow-associated brachial artery dilation in glucose-tolerant, insulin-resistant first degree relatives of subjects with type 2 diabetes [abstract]. Diabetologia 1998; 41.
17. Rocchini AP, Moorehead C, Katch V, Key J, Finta KM. Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 1992; 19: 615-20.
18. Kaplan NM. Multiple risk factors for coronary heart disease in patients with hypertension. J Hypertens 1995; 13 Suppl: S1-5.
19. Laffer CL, Elijovich F. Suboptimal outcome of management of metabolic cardiovascular risk factors in Hispanic patients with essential hypertension. Hypertension 1995; 26: 1079-84.
20. Nilsson P, Andersson DK, Andersson PE, et al. Cardiovascular risk factors in treated hypertensives - a nation-wide, cross-sectional study in Sweden. J Intern Med 1993; 233: 239-45.
21. Black HR. The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol 1990; 15 Suppl 5: S26-38.
22. Superko HR, Haskell WL, Krauss RM. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993; 101: 1-8.
23. Weber MA. Hypertension with concomitant conditions: the changing role of beta-adrenoceptor blockade. Am Heart J 1991; 121: 716-23.
24. Black HR. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1991; 121: 707-15.
25. Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993; 33: 286-91.
26. Salonen JT, Lakka TA, Lakka HM, Valkonen VP, Everson SA, Kaplan GA. Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. Diabetes 1998; 47: 270-5.
27. Middeke M, Richter WO, Schwandt P, Beck B, Holzgreve H. Normalization of lipid metabolism alter withdrawal from antihypertensive long-term therapy with beta blockers and diuretics. Arteriosclerosis 1990; 10: 145-7.
28. Mykkanen L, Kuusisto J, Pyorala K, Laakso M, Haffner SM. Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens 1994; 12: 1425-32.
29. Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? Br Med J 1989; 298: 1147-52.
30. Samuelsson O, Hedner T, Berglund G, Persson B, Andersson OK, Wilhelmsen L. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Göteborg, Sweden. J Hum Hypertens 1994; 8: 257-63.
31. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
32. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-20.
33. Lithell H, Pollare T, Berne C. Effects of long-term antihypertensive treatment on glucose metabolism. Diabetes Metab 1989; 15: 359-61.
34. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73.
35. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128: 1177-83.
36. Henriksen EJ, Jacob S, Augustin HJ, Dietze GJ. Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 1996; 45 Suppl 1: S125-8.
37. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7: 551-9.
38. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment. J Intern Med 1994; 236: 37-42.
39. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 1995; 9: 137-41.
40. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992; 1: 92-101.
41. Pollare T, Lithell H, Selinus I, Berre C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989; 298: 1152-7.
42. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-9.
43. Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994; 43: 455-61.
44. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilolmetoprolol study. J Hypertens 1996; 14: 489-94.
45. Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low-and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38: 853-9.
46. Moan A, Hoieggen A, Seljeflot I, et al. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093-7.
47. Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. Br Med J 1990; 300: 902-3.
48. Feskens EJ, Tuomilehto J, Stengard JH, Pekkanen J, Nissinen A, Kromhout D. Hypertension and overweight associated with hyperinsulinaemia and glucose tolerance: a longitudinal study of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetologia 1995; 38: 839-47.
49. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb 1991; 11: 1192-203.
50. Frick MH, Cox DA, Himanen P, et al. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. Am J Cardiol 1987; 59: 61G-7.
51. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia 1996; 39: 1201-7.
52. Swislocki AL. Impaired insulin clearance in essential hypertension. J Hum Hypertens 1994; 8: 185-90.
53. Lithell H, Andersson PE. Metabolic effects of carvedilol in hypertensive patients. Eur J Clin Pharmacol 1997; 52: 13-7.
54. Hansen O, Johansson BW, Nilsson Ehle P, et al. Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects. J Cardiovasc Pharmacol 1994; 24: 853-9.
55. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990; 13: 1109-11.
56. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991; 14 Suppl 4: 39-47.
57. Malminiemi K, Lahtela J, Malminiemi O, Ala Kaila K, Huupponen R. Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. J Cardiovasc Pharmacol 1998; 31: 140-5.
58. Malminiemi K. Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 1995; 9: 295-304.
59. Hauf Zachariou U, Blackwood RA, Gunawardena KA, O'Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997; 52: 95-100.
60. Jacob S, Fogt DL, Dietze GJ, Henriksen EJ. The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. Life Sci 1999; 64: 2071-9.
61. Yue TL, Mckenna PJ, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993; 22: 922-8.
62. Mehta JL, Lopez LM, Chen L, Cox OE. Alterations in nitric oxide synthase activity, Superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 1994; 74: 901-5.
63. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996; 27: 532-8.
64. Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998; 21: 631-6.
65. Rosen P, Ballhausen T, Bloch W, Addicks K. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 1995; 38: 1157-68.
66. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 1995; 44: 363-8.
67. Sadasivudu B, Sasikala M, Sailaja V, Reddy SS. Serum malondialdehyde, insulin, glucose and lipid profile in hypertension. Med Sci Res 1997; 25: 631-3.
68. Wiemer G, Linz W, Hatrik S, Scholkens BA, Malinski T. Angiotensin-converting enzyme inhibition alters nitric oxide and Superoxide release in normotensive and hypertensive rats. Hypertension 1997; 30: 1183-90.
69. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzynie inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-6.
70. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
71. Hansson L, Zanchetti A, Carruthers G, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.